Search Results - "Rosado, A Andrés"

1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting by Román, AB Fernández, Lázaro, C Bravo, Fernández, J Letellez, Muñoz, N Herrero, Rosado, A Andrés, Lopez, C Mayo, Gutierrez, MDM Garcia, Gil, M Garcia

“…BackgroundNivolumab (NIV) is a monoclonal antibody for patients with pre-treated advanced nonsquamous non–small-cell lung cancer (NSCLC). It is necessary to…”
Get full text

4CPS-155 Comparative study for evaluation of the pain, ease of use and preference between two adalimumab administration devices: study adap2017 by Muñoz, N Herrero, Rosado, A Andrés, Muniesa, B Hernández, Lázaro, C Bravo, Román, AB Fernández, Alonso, A Pou, Nasarre, A Ontañón, Gutiérrez, MDM García, López, C Mayo, Gil, M García

“…BackgroundAdalimumab is a monoclonal antibody indicated in immunomediate inflammatory diseases for subcutaneous administration by two different devices:…”
Get full text

DI-095 Possible severe eosinophilia induced by dimethyl fumarate in relapsing remitting multiple sclerosis by Román, AB Fernández, Nasarre, A Ontañón, Alonso, A Pou, Rosado, A Andrés, López, C Mayo, Muñoz, N Herrero, Gomez, F, Gil, M García

“…BackgroundDimethyl fumarate (DMF) is prescribed for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS). Although mild to…”
Get full text

PS-053 Severe thrombocytopenia induced by regorafenib in a metastatic colon cancer patient: A case report by Carmen, ML, Fernández, J Letéllez, Clemente, Y Castellanos, Rosado, A Andrés, Román, AB Fernandez, García, B Candel, Gil, M García

“…BackgroundRegorafenib is the third line of treatment used in metastatic colon cancer. One of the most frequent adverse effects of regorafenib is…”
Get full text

4CPS-199 Assessment of medication reconciliation in chronic complex patients by Andres Rosado, A, Gomez Lluch, T, Lorenzo Gimenez, S, Pedraza Cezon, LA

“…BackgroundTransitions in care put the patients at risk for medication error as a result of poor communication and information loss. Medication reconciliation…”
Get full text

1ISG-019 A cost-effectiveness analysis of biological therapies for moderate to severe psoriasis by Rosado, A Andres, Román, AB Fernández, Muñoz, N Herrero, Gil, M García

“…BackgroundBiological therapies (BT) have been a breakthrough in the treatment of psoriasis. Compared to conventional therapies, biologics are more effective…”
Get full text

PS-059 Aripiprazole induced dysphagia: A case report by Rosado, A Andres, Clemente, Y Castellanos, López, C Mayo, Román, AB Fernández, Muñoz, N Herrero, Gil, M Garcia

“…BackgroundDysphagia is an uncommon adverse reaction caused by psychotropic drugs. It is a principal manifestation of extrapyramidal symptoms and the main…”
Get full text